Justin Mann, MD
Radiation Oncology · Camden, NJNPI 1710326095
Payments from drug & device makers
What this record shows
The money is spread across several categories — travel and lodging (49.6%), consulting fees and food and beverage — rather than concentrated in one kind of arrangement. 6 manufacturers reported payments, led by Novocure Inc. at 49.0% of the total. Reporting peaked in 2023 at $1,622 and has fallen 95.8% since, to $69 in 2025.
Across 13 payments — averaging $260.14 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Novocure Inc.$2K
- Brainlab, Inc.$2K
- Novartis$48
- Bayer$47
- Elekta, Inc.$28
- GT Medical Technologies, Inc$21
What the payments were for
- Consulting fees$1,50044%
- Travel & lodging$1,67850%
- Food & beverage$2046%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Novocure Inc. | 5 | $1,656 |
| Brainlab, Inc. | 2 | $1,581 |
| Novartis | 2 | $48 |
| Bayer | 2 | $47 |
| Elekta, Inc. | 1 | $28 |
| GT Medical Technologies, Inc | 1 | $21 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$3,382 in reported general payments places this provider in the 85th percentile of 132 radiation oncology providers in New Jersey.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Dexamethasone | 93 | $1,158 |
| Lidocaine Hcl ViscousLidocaine Hcl | 49 | $566 |
| Gabapentin | 17 | $259 |
| Methylprednisolone | 23 | $130 |
| Silver Sulfadiazine | 17 | $120 |
| Oxycodone Hcl | 16 | $115 |
| Lorazepam | 36 | $40 |
| Pantoprazole Sodium | 12 | $36 |
Paid to pharmacies, not to this prescriber.
Other radiation oncology in Camden
- Megan MezeraCamden$4K
- Clarissa HensonCamden$2K
- Anthony DragunCamden$2K
- Spencer PoisetCamden$1K
- Michael GreenbergCherry Hill$335K
- Glen GejermanHackensack$180K
- Marc RudoltzWest Orange$166K
- Salma JabbourNew Brunswick$163K
- Edward SoffenMonroe Twp$50K
- Adnan DanishWayne$45K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.